| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8926165 | NefrologÃa Latinoamericana | 2017 | 12 Pages |
Abstract
The quality of the evidence for the different options available for rejection treatment is low. The treatment of cellular rejection has not changed in the last decades and is based on corticosteroids and / or thymoglobulin. Treatment of antibody-mediated rejection is based on the removal of antibodies by immunoadsorption or plasmapheresis, with great variability between transplant centres in terms of complementary treatments (steroids, polyvalent human gammaglobulin, bortezomib, rituximab and/or eculizumab) in order to prevent their production.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Mariana Seija, Marcelo Nin, Rossana Astesiano, Rúben Coitiño, José Santiago, Soledad Ferrari, Oscar Noboa, Francisco González-Martinez,